State Key Laboratory of Medical Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
Department of Thoracic Surgery, Baodi Clinical College, Tianjin Medical University, Tianjin, China; Department of Child Health Care, Kunshan Maternity and Child Health Care Institute, Kunshan, China.
Mol Cell Proteomics. 2024 May;23(5):100756. doi: 10.1016/j.mcpro.2024.100756. Epub 2024 Mar 28.
In orthotopic mouse tumor models, tumor progression is a complex process, involving interactions among tumor cells, host cell-derived stromal cells, and immune cells. Much attention has been focused on the tumor and its tumor microenvironment, while the host's macroenvironment including immune organs in response to tumorigenesis is poorly understood. Here, we report a temporal proteomic analysis on a subcutaneous tumor and three immune organs (LN, MLN, and spleen) collected on Days 0, 3, 7, 10, 14, and 21 after inoculation of mouse forestomach cancer cells in a syngeneic mouse model. Bioinformatics analysis identified key biological processes during distinct tumor development phases, including an initial acute immune response, the attack by the host immune system, followed by the adaptive immune activation, and the build-up of extracellular matrix. Proteomic changes in LN and spleen largely recapitulated the dynamics of the immune response in the tumor, consistent with an acute defense response on D3, adaptive immune response on D10, and immune evasion by D21. In contrast, the immune response in MLN showed a gradual and sustained activation, suggesting a delayed response from a distal immune organ. Combined analyses of tumors and host immune organs allowed the identification of potential therapeutic targets. A proof-of-concept experiment demonstrated that significant growth reduction can be achieved by dual inhibition of MEK and DDR2. Together, our temporal proteomic dataset of tumors and immune organs provides a useful resource for understanding the interaction between tumors and the immune system and has the potential for identifying new therapeutic targets for cancer treatment.
在原位小鼠肿瘤模型中,肿瘤进展是一个复杂的过程,涉及肿瘤细胞、宿主细胞来源的基质细胞和免疫细胞之间的相互作用。人们非常关注肿瘤及其肿瘤微环境,而宿主的宏观环境(包括对肿瘤发生的免疫器官)却知之甚少。在这里,我们报告了在同种小鼠模型中接种小鼠前胃癌细胞后第 0、3、7、10、14 和 21 天采集的皮下肿瘤和三个免疫器官(LN、MLN 和脾)的时间蛋白质组学分析。生物信息学分析确定了不同肿瘤发展阶段的关键生物学过程,包括最初的急性免疫反应、宿主免疫系统的攻击、随后的适应性免疫激活以及细胞外基质的构建。LN 和脾中的蛋白质组变化很大程度上再现了肿瘤中免疫反应的动力学,与 D3 上的急性防御反应、D10 上的适应性免疫反应和 D21 上的免疫逃避一致。相比之下,MLN 中的免疫反应显示出逐渐和持续的激活,表明来自远端免疫器官的延迟反应。肿瘤和宿主免疫器官的综合分析允许鉴定潜在的治疗靶点。一项概念验证实验表明,双重抑制 MEK 和 DDR2 可显著减少肿瘤生长。总之,我们的肿瘤和免疫器官的时间蛋白质组数据集为理解肿瘤与免疫系统的相互作用提供了有用的资源,并有可能为癌症治疗确定新的治疗靶点。